New Two-Pronged attack aims to stop rare bone cancer from spreading
NCT ID NCT07115667
Summary
This study is testing whether adding a new type of antibody drug to standard radiation treatment can better control a rare bone cancer called solitary bone plasmacytoma. The goal is to prevent the cancer from progressing into a more serious disease called multiple myeloma. The trial will enroll 21 adults who have not had prior treatment for this condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLITARY BONE PLASMACYTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
RECRUITINGTianjin, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.